Personalized medicine – p53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer | springermedizin.at

Springer Medizin Österreich

nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2008 | Short review

Personalized medicine – p53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer

verfasst von: D. Kandioler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Anzeige

Vorheriger Artikel Proteomics, a new tool to monitor cancer therapy?

Nächster Artikel Can we tailor neoadjuvant (primary) systemic therapy for breast cancer?

Titel: Personalized medicine – p53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer
verfasst von: D. Kandioler
Publikationsdatum: 01.09.2008
Verlag: Springer-Verlag
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2008
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-008-0049-7

Weitere Artikel der Ausgabe 3/2008

Striking response with bevacizumab and chemotherapy in a woman with heavily pretreated breast cancer: a case presentation

Case report

Treatment options in localised and metastatic renal cell carcinoma

Short review

Announcement

Announcement

Therapeutic options for the treatment of infections with multiresistant grampositive bacteria in oncological patients

Short review

CECOG at ASCO 2008

CECOG News

Proteomics, a new tool to monitor cancer therapy?

Review